England HPV vaccination program yields 80% cervical cancer mortality drop and zero deaths in vaccinated cohorts through 2024

Researchers Sasieni and Falcaro linked HPV vaccination coverage records to cervical cancer mortality statistics across birth cohorts in England. They compared vaccinated groups with earlier unvaccinated cohorts using population-level data from the national screening and cancer registries. The analysis showed an 80% relative reduction in deaths for 2015-2019 followed by zero deaths in the most recent period, consistent with the timing of the school-based program that began in 2008 and achieved high coverage.

These population-level findings align with earlier RCT evidence from trials such as PATRICIA and FUTURE that established prevention of high-grade cervical intraepithelial neoplasia. Observational studies in Australia and Sweden have reported parallel reductions in incidence but fewer direct mortality analyses. The current data strengthen the case for early adolescent vaccination while highlighting that screening improvements and possible herd effects may also contribute to observed declines.

Global equity gaps persist: high-income countries with early programs approach elimination targets by 2040, yet WHO data show fewer than 25% of low-income countries have introduced routine HPV vaccination. Continued follow-up beyond age 30 is required because mortality risk rises later and genotype distribution may shift. Individual-level linkage studies and extended cohort monitoring will be needed to confirm durability and isolate vaccination effects from screening.